<DOC>
	<DOCNO>NCT01192165</DOCNO>
	<brief_summary>The purpose study determine dose GSK1120212 give safely combination least one drug already approve treat cancer . This study test safety 6 different GSK1120212 study treatment combination ( GSK1120212 plus either docetaxel , erlotinib , pemetrexed , pemetrexed + carboplatin , pemetrexed + cisplatin , nab-paclitaxel ) . The dos identify study may use future trial test whether combination treatment safe effective therapy subject metastatic lung and/or pancreatic cancer .</brief_summary>
	<brief_title>Safety Tolerability Study GSK1120212 , MEK Inhibitor , Combination With Docetaxel , Erlotinib , Pemetrexed , Pemetrexed + Carboplatin , Pemetrexed + Cisplatin , Nab-Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>The subject solid tumor . Expansion cohort limit nonsmall cell lung cancer and/or pancreatic cancer without KRAS mutation . Tumor progression follow least one prior standard therapy , subject refuse standard therapy , standard therapy exists . The subject radiographically measurable tumor . The subject able carry daily life activity without difficulty . The subject able swallow retain oral medication . The subject significant side effect previous anticancer treatment . The subject adequate organ blood cell count . Sexually active subject must use medically acceptable method contraception course study . The subject major surgery receive certain type cancer therapy within 23 week start study . The subject brain tumor . Current severe , uncontrolled systemic disease . History clinically significant heart , lung , eye/vision problem . The subject high blood pressure wellcontrolled medication . The subject permanent pacemaker . The subject pregnant breastfeeding . Positive Hepatitis B , Hepatitis C , HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Taxotere</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Trametinib</keyword>
	<keyword>GSK1120212</keyword>
	<keyword>Tarceva</keyword>
	<keyword>KRAS</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>nab-Paclitaxel</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Alimta</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Erlotinib</keyword>
</DOC>